Dimerix Annual Update 2015; Lists on the ASX & Commences Phase II Clinical Study

Dimerix Bioscience has made substantial progress in a number of corporate and operational areas in 2015. In July, Dimerix Bioscience was acquired by Sun Biomedical (who subsequently changed its name to Dimerix Limited ASX:DXB). On 17th December, Dimerix announced the appointment of Dr Liz Jazwinska as a non executive director. Dr Jazwinska brings more than 25 years experience in Science and Business with Senior Roles in Industry, Academia and Government in Australia, New Zealand, UK, and Asia Pacific, including 7 years at Johnson and Johnson Research Pty Ltd.

Dimerix’s lead clinical program, a Phase II study in Chronic Kidney Disease, DMX-200, is now recruiting patients with the company aiming to provide interim data in mid 2016. Upon successful results, Dimerix intends to pursue the registration of a product for an orphan indication, and was recently granted Orphan Drug Designation for DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) by the FDA.

ABOUT DIMERIX

Dimerix is an Australian biotech company developing and commercialising novel drug therapies targeted at unmet patient needs, with the lead clinical program targeting chronic kidney disease (CKD).

Dimerix conducts its laboratory operations via contracts with the University of Western Australia and the Harry Perkins Institute of Medical Research, WA. Dimerix is working with established clinical research organisations for its clinical studies.